Introduction
The parietal cortex is located posterior to the frontal lobe. It is structurally divided into the superior, middle and inferior gyri. The most anterior portion of the parietal lobe forms the post-central gyrus, the somatosensory cortex. Posterior to this are the parietal association regions, and the visual regions of the posterior parietal cortex, involved in visuospatial processing.
Schizophrenia has been associated with altered structure and function of the parietal lobe. Understanding of any brain alterations in people with schizophrenia may provide insight into changes in brain development associated with the illness onset or progression. Reviews contained in this technical summary reflect both structural (MRI, DTI), and functional imaging (fMRI, PET) studies, as well as metabolic investigations (MRS) of the parietal lobe in schizophrenia.
Method
We have included only systematic reviews (systematic literature search, detailed methodology with inclusion/exclusion criteria) published in full text, in English, from the year 2000 that report results separately for people with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder or first episode schizophrenia. Reviews were identified by searching the databases MEDLINE, EMBASE, CINAHL, Current Contents, PsycINFO and the Cochrane library. Hand searching reference lists of identified reviews was also conducted. When multiple copies of reviews were found, only the most recent version was included. Reviews with pooled data are prioritised for inclusion.
Review reporting assessment was guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist, which describes a preferred way to present a meta-analysis 1 . Reviews rated as having less than 50% of items checked have been excluded from the library. The PRISMA flow diagram is a suggested way of providing information about studies included and excluded with reasons for exclusion. Where no flow diagram has been presented by individual reviews, but identified studies have been described in the text, reviews have been checked for this item. Note that early reviews may have been guided by less stringent reporting checklists than the PRISMA, and that some reviews may have been limited by journal guidelines.
Evidence was graded using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group approach where high quality evidence such as that gained from randomised controlled trials (RCTs) may be downgraded to moderate or low if review and study quality is limited, if there is inconsistency in results, indirect comparisons, imprecise or sparse data and high probability of reporting bias. It may also be downgraded if risks associated with the intervention, or other matter under review, are high. Conversely, low quality evidence such as that gained from observational studies may be upgraded if effect sizes are large, there is a dose dependent response or if results are reasonably consistent, precise and direct with low associated risks (see end of table for an explanation of these terms) 2 . The resulting table represents an objective summary of the available evidence, although the conclusions are solely the opinion of staff of NeuRA (Neuroscience Research Australia).
Results
We found twelve systematic reviews that met our inclusion criteria [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . • Moderate to low quality evidence suggests reductions in white matter integrity in the parietal lobe, including temporo-parietal and parieto-occipital regions.
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• High quality evidence suggests greater reductions over time in parietal white matter in schizophrenia than in controls.
Functional changes: fMRI, PET, MRS
• Moderate quality evidence suggests reduced functional activation of the right inferior parietal lobe in schizophrenia during episodic memory encoding and executive functioning tasks. Regions of the inferior parietal cortex and precuneus show increased activity during executive functioning tasks.
• Moderate to low quality evidence suggests abnormal activity (mostly increased) in the parietal cortex of first-degree relatives of people with schizophrenia during cognitive control, working memory and language processing tasks. No difference was reported in long-term memory tasks.
• Moderate to low quality evidence shows decreased N-acetyl aspartate levels in parietal cortex grey matter in schizophrenia compared to healthy controls. 
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Comparison
Grey matter volume in schizophrenia patients vs. healthy controls.
Summary of evidence
Moderate quality evidence (large sample sizes, direct, unable to assess consistency or precision) suggests bilateral reductions in grey matter volume in the anterior cingulate/medial prefrontal cortex, the insula/operculum, the posterior cingulate, thalamus, medial temporal lobe, and subgenual cingulate; as well as lateralised differences in the left middle and inferior frontal gyri, the left fusiform gyrus, and left inferior parietal gyrus in people with schizophrenia.
Grey matter volume
Meta-analysis was performed using Activation Likelihood Estimate (ALE) analysis on Voxel-Based Morphometry MRI studies.
FWHM 12mm, FDR corrected at p < 0.05 37 studies, N = 3336
Decreased grey matter was reported in the left inferior parietal gyrus.
Pooled analysis identified 15 clusters of reduced grey matter, encompassing foci in the frontal, temporal, limbic and subcortical regions.
Clusters where volume reductions were significantly more frequent than grey matter concentration reductions (grey matter as a proportion of the whole brain volume);
Right pre and post-central gyri: 
Consistency in results
No measure of consistency is reported.
Precision in results
No confidence intervals reported 
Directness of results
Grey matter volume
Meta-analysis was performed using Anatomical Likelihood Estimate (ALE) analysis on Voxel-Based Morphometry MRI studies. 
Consistency in results
Precision in results
No confidence intervals are provided.
Directness of results Direct
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Comparison Functional activation in relatives of people with schizophrenia
Parietal lobe
Explanation of technical terms * Bias has the potential to affect reviews of both RCT and observational studies. Forms of bias include; reporting bias -selective reporting of results, publication bias -trials that are not formally published tend to show less effect than published trials, further if there are statistically significant differences between groups in a trial, these trial results tend to get published before those of trials without significant differences; language bias -only including English language reports; funding bias -source of funding for the primary research with selective reporting of results within primary studies; outcome variable selection bias; database biasincluding reports from some databases and not others; citation bias -preferential citation of authors. Trials can also be subject to bias when evaluators are not blind to treatment condition and selection bias of participants if trial samples are small 15 . † Different effect measures are reported by different reviews. ALE analysis (Anatomical Likelihood Estimate) refers to a voxel-based metaanalytic technique for structural imaging in which each point of statistically significant structural difference is spatially smoothed into Gaussian distribution space, and summed to create a statistical map estimating the likelihood of difference in each voxel, as determined by the entire set of included studies. Incorporated with the Genome Scan Meta-analysis (GSMA), the meta-analysis of coordinates from multiple studies can be weighted for sample size to create a random effect analysis. The ALE statistic (if reported) represents the probability of a group difference occurring at each voxel included in the analysis.
Fractional similarity network analysis refers to a network analysis technique in which secondary networks are identified within the larger framework of activity, creating a matrix for regional co-activity.
Weighted mean difference scores refer to mean differences between treatment and comparison groups after treatment (or occasionally pre to post treatment) and in a randomised trial there is an assumption that both groups are comparable on this measure prior to treatment. Standardised mean differences are divided by the pooled standard deviation (or the standard deviation of one group when groups are homogenous) which allows results from different scales to be combined and compared. Each study's mean difference is then given a weighting depending on the size of the sample and the variability in the data. Less than 0.4 represents a small effect, around 0.5 a medium effect, and over 0.8 represents a large effect 15 .
Odds ratio (OR) or relative risk (RR) refers to the probability of a reduction (< 1) or an increase (> 1) in a particular outcome in a treatment group, or a group exposed to a risk factor, relative to the comparison group. For example, a RR of 0.75 translates to a reduction in risk of an outcome of 25% relative to those not receiving the treatment or not exposed to the risk factor. Conversely, a RR of 1.25 translates to an increased risk of 25% relative to those not receiving treatment or not having been exposed to a risk factor. A RR or OR of 1.00 means there is no difference between groups. A medium effect is considered if RR > 2 or < 0.5 and a large effect if RR > 5 or < 0.2 16 . lnOR stands for logarithmic OR where a lnOR of 0 shows no difference between groups. Hazard ratios variables. Standardised regression coefficients represent the change being in units of standard deviations to allow comparison across different scales.Reliability and validity refers to how accurate the instrument is. Sensitivity is the proportion of actual positives that are correctly identified (100% sensitivity = correct identification of all actual positives) and specificity is the proportion of negatives that are correctly identified (100% specificity = not identifying anyone as positive if they are truly not). ‡ Inconsistency refers to differing estimates of treatment effect across studies (i.e. heterogeneity or variability in results) that is not explained by subgroup analyses and therefore reduces confidence in the effect estimate. I² is the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) -0% to 40%: heterogeneity might not be important, 30% to 60%: may represent moderate heterogeneity, 50% to 90%: may represent substantial heterogeneity and 75% to 100%: considerable heterogeneity. I² can be calculated from Q (chi-square) for the test of heterogeneity with the following formula; § Imprecision refers to wide confidence intervals indicating a lack of confidence in the effect estimate. Based on GRADE recommendations, a result for continuous data (standardised mean differences, not weighted mean differences) is considered imprecise if the upper or lower confidence limit crosses an effect size of 0.5 in either direction, and for binary and correlation data, an effect size of 0.25. GRADE also recommends downgrading the evidence when sample size is smaller than 300 (for binary data) and 400 (for continuous data), although for some topics, this criteria should be relaxed 17 . ║ Indirectness of comparison occurs when a comparison of intervention A versus B is not available but A was compared with C and B was compared with C, which allows indirectcomparisons of the magnitude of effect of A versus B. Indirectness of population, comparator and or outcome can also occur when the available evidence regarding a particular population, intervention, comparator, or outcome is not available so is inferred from available evidence. These inferred treatment effect sizes are of lower quality than those gained from head-to-head comparisons of A and B.
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